NDAORALTABLET2 Generics Approved
Approved
Jun 1995
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMITREX (sumatriptan) is an oral small-molecule triptan approved in 1995 for the acute treatment of migraine headaches with or without aura. It works as a selective 5-HT1B/1D receptor agonist that constricts cranial blood vessels and reduces pain-signaling neuropeptides. The drug remains a foundational migraine therapy decades after launch.
$0.232MPart D
LOE ApproachingDeclining
Brand is in late-stage managed decline; commercial teams are focusing on generic transition planning and defensive strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.
Started Jun 2020
10 enrolled
Healthy Volunteers
Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)
Started Jan 2018
19 enrolled
Migraine Disorders
A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants
Started Oct 2017
40 enrolled
Healthy
Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea
Started Jun 2017
36 enrolled
Migraine With and Without Aura
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
Started Mar 2017
42 enrolled
Migraine
Worked on IMITREX at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.